246 related articles for article (PubMed ID: 31864957)
1. Response rates and survival to systemic therapy after immune checkpoint inhibitor failure in recurrent/metastatic head and neck squamous cell carcinoma.
Pestana RC; Becnel M; Rubin ML; Torman DK; Crespo J; Phan J; Hanna E; Bell D; Glisson BS; Johnson JM; Lee JJ; Ferrarotto R
Oral Oncol; 2020 Feb; 101():104523. PubMed ID: 31864957
[TBL] [Abstract][Full Text] [Related]
2. Initial analysis of the synergy of programmed cell death-1 (PD-1) inhibitor and concurrent chemoradiotherapy treatment for recurrent/metastatic head and neck squamous cell carcinoma patients.
Li L; Chen L; Yan L; Guo Y; Li F; Fan M; Lan M; Lai X; Zhou J; Huang Y; Xu P; Lang J; Feng M
Radiat Oncol; 2023 Jul; 18(1):109. PubMed ID: 37403098
[TBL] [Abstract][Full Text] [Related]
3. Response to salvage chemotherapy after progression on immune checkpoint inhibitors in patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck.
Saleh K; Daste A; Martin N; Pons-Tostivint E; Auperin A; Herrera-Gomez RG; Baste-Rotllan N; Bidault F; Guigay J; Le Tourneau C; Saada-Bouzid E; Even C
Eur J Cancer; 2019 Nov; 121():123-129. PubMed ID: 31574417
[TBL] [Abstract][Full Text] [Related]
4. Salvage Chemotherapy After Nivolumab for Recurrent or Metastatic Head and Neck Carcinoma.
Fushimi C; Okamoto I; Matsuki T; Masubuchi T; Okada T; Sato H; Tsukahara K; Kondo T; Yamashita T; Hanyu K; Omura GO; Takahashi H; Tada Y; Miura K
Anticancer Res; 2020 Sep; 40(9):5277-5283. PubMed ID: 32878817
[TBL] [Abstract][Full Text] [Related]
5. Clinical Outcomes of Cetuximab and Paclitaxel after Progression on Immune Checkpoint Inhibitors in Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma.
Suzuki S; Toyoma S; Kawasaki Y; Koizumi K; Iikawa N; Shiina K; Endo T; Abe T; Kouga T; Yamada T
Medicina (Kaunas); 2021 Oct; 57(11):. PubMed ID: 34833369
[No Abstract] [Full Text] [Related]
6. Efficacy of second-line chemotherapy or immune checkpoint inhibitors for patients with a prolonged objective response (≥ 6 months) after first-line therapy for recurrent or metastatic head and neck squamous cell carcinoma: a retrospective study.
Vienne A; Collet L; Chevalier T; Borel C; Tardy M; Huguet F; Richard S; Salas S; Saada-Bouzid E; Fayette J; Daste A
BMC Cancer; 2023 Jul; 23(1):663. PubMed ID: 37452287
[TBL] [Abstract][Full Text] [Related]
7. Efficacy and safety of anti-EGFR agents administered concurrently with standard therapies for patients with head and neck squamous cell carcinoma: a systematic review and meta-analysis of randomized controlled trials.
Tian Y; Lin J; Tian Y; Zhang G; Zeng X; Zheng R; Zhang W; Yuan Y
Int J Cancer; 2018 Jun; 142(11):2198-2206. PubMed ID: 29143328
[TBL] [Abstract][Full Text] [Related]
8. Treatment sequence of cetuximab and immune checkpoint inhibitor in head and neck squamous cell carcinoma differentially affects outcomes.
Park JC; Durbeck J; Clark JR; Faden DL
Oral Oncol; 2020 Dec; 111():105024. PubMed ID: 33065374
[TBL] [Abstract][Full Text] [Related]
9. Outcome of chemotherapy following nivolumab treatment for recurrent and/or metastatic head and neck squamous cell carcinoma.
Wakasaki T; Yasumatsu R; Uchi R; Taura M; Matsuo M; Komune N; Nakagawa T
Auris Nasus Larynx; 2020 Feb; 47(1):116-122. PubMed ID: 31128940
[TBL] [Abstract][Full Text] [Related]
10. Combination therapy with immune checkpoint inhibitors in recurrent or metastatic squamous cell carcinoma of the head and neck: A meta-analysis.
Chen L; Mo DC; Hu M; He W; Yang QW; Tang J
Int Immunopharmacol; 2023 Jun; 119():110270. PubMed ID: 37150013
[TBL] [Abstract][Full Text] [Related]
11. Clinical outcomes of immune checkpoint inhibitors for patients with recurrent or metastatic head and neck cancer: real-world data in Korea.
Kim H; Kwon M; Kim B; Jung HA; Sun JM; Lee SH; Park K; Ahn MJ
BMC Cancer; 2020 Aug; 20(1):727. PubMed ID: 32758163
[TBL] [Abstract][Full Text] [Related]
12. Both combined or sequential use with immune checkpoint inhibitors on cetuximab-treated patients with recurrent or metastatic head and neck squamous cell carcinoma improve the overall survival.
Lien MY; Wang TH; Hsieh CY; Tsai MH; Hua CH; Cheng FM; Chung WH; Tang CH; Chia-Hsun Hsieh J
Oral Oncol; 2021 Aug; 119():105380. PubMed ID: 34146822
[TBL] [Abstract][Full Text] [Related]
13. The Optimal Second-Line Systemic Treatment Model for Recurrent and/or Metastatic Head and Neck Squamous Cell Carcinoma: A Bayesian Network Meta-Analysis.
Zhan ZJ; Yao WY; Zhang F; Qiu WZ; Liao K; Feng JH; Tan JY; Liu H; Yuan TZ; Zheng RH; Yuan YW
Front Immunol; 2021; 12():719650. PubMed ID: 34413862
[TBL] [Abstract][Full Text] [Related]
14. Real-world time on treatment with immuno-oncology therapy in recurrent/metastatic head and neck squamous cell carcinoma.
Ramakrishnan K; Liu Z; Baxi S; Chandwani S; Joo S; Chirovsky D
Future Oncol; 2021 Aug; 17(23):3037-3050. PubMed ID: 34044594
[TBL] [Abstract][Full Text] [Related]
15. First-line treatment with chemotherapy plus cetuximab in Chinese patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck: Efficacy and safety results of the randomised, phase III CHANGE-2 trial.
Guo Y; Luo Y; Zhang Q; Huang X; Li Z; Shen L; Feng J; Sun Y; Yang K; Ge M; Zhu X; Wang L; Liu Y; He X; Bai C; Xue K; Zeng Y; Chang X; Chen W; Lin T
Eur J Cancer; 2021 Oct; 156():35-45. PubMed ID: 34418665
[TBL] [Abstract][Full Text] [Related]
16. Outcomes and Biomarkers of Immune Checkpoint Inhibitor Therapy in Patients with Refractory Head and Neck Squamous Cell Carcinoma: KCSG HN18-12.
Lee YG; Chang H; Keam B; Chun SH; Park J; Park KU; Shin SH; An HJ; Lee KE; Lee KW; Kim HR; Kim SB; Ahn MJ; Hwang IG
Cancer Res Treat; 2021 Jul; 53(3):671-677. PubMed ID: 33285051
[TBL] [Abstract][Full Text] [Related]
17. Exploring long-term responses to immune checkpoint inhibitors in recurrent and metastatic head and neck squamous cell carcinoma.
Bila M; Franken A; Van Dessel J; Garip M; Meulemans J; Willaert R; Hoeben A; Vander Poorten V; Clement PM
Oral Oncol; 2024 Feb; 149():106664. PubMed ID: 38113661
[TBL] [Abstract][Full Text] [Related]
18. HGF-Induced PD-L1 Expression in Head and Neck Cancer: Preclinical and Clinical Findings.
Boschert V; Teusch J; Aljasem A; Schmucker P; Klenk N; Straub A; Bittrich M; Seher A; Linz C; Müller-Richter UDA; Hartmann S
Int J Mol Sci; 2020 Nov; 21(22):. PubMed ID: 33233528
[TBL] [Abstract][Full Text] [Related]
19. Response rates to single-agent chemotherapy after exposure to immune checkpoint inhibitors in advanced non-small cell lung cancer.
Schvartsman G; Peng SA; Bis G; Lee JJ; Benveniste MFK; Zhang J; Roarty EB; Lacerda L; Swisher S; Heymach JV; Fossella FV; William WN
Lung Cancer; 2017 Oct; 112():90-95. PubMed ID: 29191606
[TBL] [Abstract][Full Text] [Related]
20. Cetuximab Treatment beyond Progression in Patients with Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma: A Nationwide Population-Based Study (THNS-2021-08).
Wang HM; Lou PJ; Yang MH; Chen TH; Lien MY; Lin JC; Chen JP; Lu WC; Lu HJ; Huang TL; Yen CJ; Wu SY; Wang HC; Hsieh MC
Target Oncol; 2024 Jan; 19(1):51-58. PubMed ID: 38285067
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
